Keywords: Pfizer, Lyrica, Ph III, Diabetes, HIV patients, Pain

Pfizer reports disappointment with Ph III trials of Lyrica in extended indications

Article | 08 May 2012

Print This

US drugs behemoth Pfizer (NYSE; PFE) had a setback with extending the use of its blockbuster drug Lyrica (pregabalin) last ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in